Thrombolex Raises $50 Million Series A Financing Led by OrbiMed

March 16, 2026

Thrombolex, Inc., a commercial-stage medical device company focused on pharmaco-mechanical lysis for thromboembolic diseases, announced the closing of a $50 million Series A equity financing led by OrbiMed. The funding is intended to expand U.S. commercialization and advance clinical evidence generation for its FDA-cleared BASHIR Endovascular Catheter (BEC) platform for pulmonary embolism and other VTE indications.

Buyers
OrbiMed
Targets
Thrombolex, Inc.
Industry
Medical Devices
Location
Pennsylvania, United States
Transaction Type
Growth capital

Explore More

Related Acquisitions

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.